Last reviewed · How we verify
TBI-223 oral suspension
TBI-223 oral suspension is a Small molecule drug developed by Global Alliance for TB Drug Development. It is currently in Phase 1 development.
At a glance
| Generic name | TBI-223 oral suspension |
|---|---|
| Sponsor | Global Alliance for TB Drug Development |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TBI-223 oral suspension CI brief — competitive landscape report
- TBI-223 oral suspension updates RSS · CI watch RSS
- Global Alliance for TB Drug Development portfolio CI
Frequently asked questions about TBI-223 oral suspension
What is TBI-223 oral suspension?
TBI-223 oral suspension is a Small molecule drug developed by Global Alliance for TB Drug Development.
Who makes TBI-223 oral suspension?
TBI-223 oral suspension is developed by Global Alliance for TB Drug Development (see full Global Alliance for TB Drug Development pipeline at /company/global-alliance-for-tb-drug-development).
What development phase is TBI-223 oral suspension in?
TBI-223 oral suspension is in Phase 1.